To confirm the effectiveness of Vidalista CT 20 mg in treating erectile dysfunction (ED), several assessments can be used. Vidalista CT 20 mg contains tadalafil, a PDE5 inhibitor, and its effectiveness is measured both subjectively and objectively.

1. Patient-reported outcomes:
The most common method is the use of questionnaires, such as the International Index of Erectile Function (IIEF-5). This tool evaluates erection frequency, firmness, maintenance, and satisfaction. Improvement in scores after taking Vidalista CT 20 indicates effectiveness.

2. Sexual performance monitoring:
Men may keep a sexual diary documenting erection quality, duration, and satisfaction during intercourse. Comparing results before and after starting Vidalista CT provides practical evidence of improvement.

3. Nocturnal penile tumescence (NPT) test:
This objective test monitors erections during sleep. If NPT improves after treatment, it suggests better erectile function, confirming the drug’s physiological effect.

4. Doppler ultrasound:
A penile Doppler ultrasound can assess blood flow in the penile arteries. Increased blood flow after taking Vidalista CT indicates effective vascular response.

5. Clinical follow-up:
Regular follow-ups with a doctor allow assessment of side effects, dose tolerance, and functional improvement, providing a comprehensive evaluation.

In summary, the effectiveness of Vidalista CT 20 mg is confirmed through patient questionnaires, sexual performance tracking, and sometimes objective tests like NPT or Doppler ultrasound, under medical supervision.